From Pricing To Patents: Hearing Signals A Potential New Focus

Sen. Cornyn recommended the Judiciary Committee initiate an inquiry into drug patents after a back-and-forth with AbbVie CEO Gonzalez over the Humira patent estate at the drug pricing hearing.

NATIONAL HARBOR, MD - MARCH 7, 2014: Senator John Cornyn (R-TX) speaks at the Conservative Political Action Conference (CPAC). - Image

The biopharma executives appearance in front of the Senate Finance Committee on Feb. 26 produced a surprisingly temperate hearing on drug pricing, but also included a unexpected and potentially worrisome turn when Sen. John Cornyn (R-Texas) recommended the Judiciary Committee pick up a whole separate line of inquiry on drug patents.

Another Congressional review on top of ongoing drug pricing hearings in the House and Senate would be another headache for...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Legislation

More from Pink Sheet